T + A方案改善免疫微环境,实现晚期HCC优质生存

Bevacizumab plus AtezolizumabImprove the Immune Microenvironment and Achieve High Quality Survival of Advanced in HCC

人类肝细胞癌(HCC)为全世界第四大肿瘤致死因素,约一半以上的HCC病人被诊断时疾病已经进展到了晚期,缺乏治疗根除的可能性。因此目前临床上晚期肝恶性肿瘤的治疗主要以全身系统性药物治疗为主。IMbrAve150研究揭示了抗血管形成药贝伐珠单抗(bevacizumab,BEVA,简称T) + 免疫检测点PD-1抑制剂阿替利珠单抗(atezolizumab,ATEZO,简称A)的T + A方法在不能直接手术切除且未进行系统处理的肝癌病人中,明显高于索拉非尼的总生存期(Overall Survival, OS)及无进展生存期(Progression free Survival, PFS),增加客观应答率(Objective Response Rate, ORR),显著延长中位生存期(Median Survival Time, MST)、明显改善患者生活质量(Quality of Life, QoL)。本文就联合治疗对晚期肝癌的获益作一综述。

Human hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death in the world. About half of HCC patients develop to advanced stage after diagnosis and have lost the chance of surgical eradication. Therefore, the current clinical treatment of advanced liver cancer is mainly based on systemic drug therapy. The IMbrAve150 study revealed that the antiangiogenic drug bevacizumab (BEVA, T) plus the immunodetection point PD-1 inhibitor atezolizumab (ATEZO, A) T + A method was significantly better than sorafenib in Overall Survival (OS) and progression-free sur-vival (PFS) in patients with liver cancer that cannot be resected directly without systematic treat-ment free Survival (PFS), increased Objective Response Rate (ORR), significantly prolonged Median Survival Time (MST), and obviously improved the Quality of life of patients Life, (QoL). This article reviews the benefits of combination therapy for advanced in liver cancer.